Hikma Pharmaceuticals allowed to conduct due diligence on GSK Egypt

Potential sale of its entire stake of 91.2% in GSK Egypt

  
Traders work at the Egyptian stock exchange in Cairo February 2, 2014.

Traders work at the Egyptian stock exchange in Cairo February 2, 2014.

REUTERS/ Mohamed Abd El Ghany
Cairo – Mubasher: The board of directors of Glaxo SmithKline (GSK Egypt) agreed to allow Hikma Pharmaceuticals Plc to conduct due diligence on the company, according to a bourse disclosure on Wednesday.

On Tuesday, the company said that its majority shareholder Glaxo Group Limited signed a non-binding term sheet with Hikma Pharmaceuticals Plc for the potential sale of its entire stake of 91.2% in GSK Egypt.

During the first nine months of 2020, GSK Egypt reported net profits of EGP 101.41 million, up from EGP 67.03 million in the corresponding period a year earlier.

Source: Mubasher

All Rights Reserved - Mubasher Info © 2005 - 2021 Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Equities